Edition:
India

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

374.07USD
17 Jan 2018
Change (% chg)

$3.86 (+1.04%)
Prev Close
$370.21
Open
$373.86
Day's High
$378.69
Day's Low
$370.28
Volume
276,919
Avg. Vol
294,606
52-wk High
$543.50
52-wk Low
$340.13

Select another date:

Tue, Jan 9 2018

Regeneron forms consortium to accelerate gene sequencing project

Regeneron Pharmaceuticals Inc on Monday announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project it believes could help accelerate new drug discovery and improve approval success rates.

UPDATE 1-Regeneron forms consortium to accelerate gene sequencing project

Jan 8 Regeneron Pharmaceuticals Inc on Monday announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project it believes could help accelerate new drug discovery and improve approval success rates.

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS, Jan 8 France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.

BRIEF-Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 Palisade Trial Of AR101 For Peanut Allergy

* AIMMUNE THERAPEUTICS - PALISADE COMPLETED IN 2017; TOPLINE RESULTS ANTICIPATED IN FEBRUARY

BRIEF-Regeneron Pharma Says Enter Letter Agreement Relating To Immuno-Oncology License,Collaboration Agreement With Sanofi

* REGENERON PHARMACEUTICALS-ON JAN 7,ENTERED LETTER AGREEMENT RELATING TO IMMUNO-ONCOLOGY LICENSE,COLLABORATION AGREEMENT WITH SANOFI BIOTECHNOLOGY SAS​

Regeneron forms consortium to accelerate gene sequencing project

Jan 8 Regeneron Pharmaceuticals Inc on Monday announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project it believes could help accelerate new drug discovery and improve approval success rates.

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

Select another date: